Drs Rapuano and Nagra of Wills Eye Hospital discuss the FDA Approval of Xiidra

This course consists of 1 module, with a total of 1 section.

Christopher J. Rapuano, MD, Chief of The Wills Eye Hospital Cornea Service and Parveen K. Nagra, MD, Wills Eye Cornea Service Staff comment on the FDA Approval of Xiidra for the treatment of signs and symptoms of dry eye disease.

The U.S. Food and Drug Administration approved Xiidra (lifitegrast ophthalmic solution) for the treatment of signs and symptoms of dry eye disease, on Monday, July 11, 2016. Xiidra is the first medication in a new class of drugs, called lymphocyte function-associated antigen 1 (LFA-1) antagonist, approved by the FDA for dry eye disease. Dry eye disease includes a group of conditions in which the eye does not produce an adequate volume of tears or when the tears are not of the correct consistency. The chance of experiencing dry eye increases with age, affecting approximately five percent of the adult population age 30-40 and 10 to 15 percent of adults over age 65, and is more common among women. When severe and left untreated, this condition can lead to pain, ulcers or scars on the part of the eye called the cornea. Dry eye can make it more difficult to perform some activities, such as using a computer or reading for an extended period of time, and it can decrease tolerance for dry environments, such as the air inside an airplane.

Wills Eye Hospital is a leader in the treatment of dry eye disease. We treat patients for dry eye disease here in Philadelphia, New Jersey and Delaware. Wills Eye doctors have been a part of the research and patients studies that are key for finding a treatment for dry eye disease.

 
To view this course, please log in or register.

Course Content

FDA Approval of Xiidra
Drs Rapuano and Nagra

Trending Topics
Complicated Cataract Cases: A Multi-Disciplinary Approach 2019 (CME)
Author/Presenter:
Glaucoma Update: Making Sense of Glaucoma Imaging and Testing (CME)
Author/Presenter:
Oculoplastics Update: Eyelid and Lacrimal Problems (CME)
Author/Presenter:
22nd Biennial Cornea Conference (CME)
Author/Presenter:
An Overview of Biologic Therapy in Ophthalmology
Author/Presenter:
Retina Update: Controversies in Retina 2018 :Debates & Discussion (CME)
Author/Presenter:
Chiefs Rounds: 65 yo F presents with Pain OS worse with Movement x5 Days, Decreased Vision x1 Day
Author/Presenter:
Chiefs Rounds: 80 yo Female Presents to WER with 6 week History Gradual Onset Blurred Vision OD
Author/Presenter:
Chiefs Rounds:47 yo M Presents for Evaluation of Poor Vision OD
Author/Presenter:
VIEW ALL
Chiefs Rounds Featured Case
What is the Diagnosis?
64yo man with shadows & cobwebs moving around his vision
Click Here to View Course
Live Streaming Chiefs' Rounds
Center for Academic Global Ophthalmology
Eyephotosystems
Sony Vision Unimpaired